Home › Diffuse Large B-Cell Lymphoma › South Dakota › Sioux Falls
Diffuse Large B-Cell Lymphoma clinical trials in Sioux Falls, SD
3 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Sioux Falls (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
- Avera Cancer Institute, Sioux Falls
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- Sanford Cancer Center ( Site 0143), Sioux Falls
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
- Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Los Angeles, CA17 studies
- Houston, TX17 studies
- Boston, MA16 studies
- Milwaukee, WI16 studies
- Nashville, TN15 studies
- Portland, OR15 studies
- Philadelphia, PA15 studies
- Durham, NC14 studies
- Dallas, TX13 studies
Other studies in Sioux Falls
- Non-Small Cell Lung Cancer19 studies
- Breast Cancer18 studies
- Ovarian Cancer16 studies
- Lung Cancer14 studies
- Cancer (all types)13 studies
- Endometrial Cancer11 studies
- Metastatic Cancer10 studies
- Colorectal Cancer9 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Triple-Negative Breast Cancer7 studies
- Heart Failure7 studies
- Prostate Cancer7 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.